{
  "nct_id": "UW 23-407",
  "age": "Adults",
  "cancer_center_accrual_goal_upper": 0,
  "data_table4": "Interventional",
  "drug_list": {
    "drug": [
      {
        "drug_name": "Sacituzumab Govitecan"
      }
    ]
  },
  "long_title": "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy (Ascent-07)",
  "management_group_list": {
    "management_group": [
      {
        "is_primary": "Y",
        "management_group_name": "HKUMed"
      }
    ]
  },
  "oncology_group_list": {
    "oncology_group": [
      {
        "group_name": "Group 1",
        "is_primary": "N"
      }
    ]
  },
  "phase": "3",
  "principal_investigator": "Dr Wendy CHAN",
  "principal_investigator_institution": "HKU",
  "program_area_list": {
    "program_area": [
      {
        "is_primary": "Y",
        "program_area_name": "Program 1"
      }
    ]
  },
  "protocol_id": null,
  "protocol_no": "",
  "protocol_target_accrual": 0,
  "protocol_type": "",
  "prior_treatment_requirements": [
    "HR+/HER2- advanced breast cancer eligible for first chemotherapy",
    "No prior use of topoisomerase I inhibitor",
    "Either one of the following:",
    "- Progressive disease (PD) on ≥2 previous lines of endocrine therapy (ET) in metastatic setting",
    "- PD within 6 months of first-line ET in metastatic setting",
    "- PD within 24 months of adjuvant ET + CDK 4/6 inhibitor and not a candidate for further ET"
  ],
  "short_title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) Breast Cancer",
  "site_list": {
    "site": []
  },
  "sponsor_list": {
    "sponsor": []
  },
  "staff_list": {
    "protocol_staff": []
  },
  "status": "open to accrual",
  "summary": "",
  "treatment_list": {
    "step": [
      {
        "arm": [
          {
            "arm_code": "Arm A",
            "arm_internal_id": 1111,
            "arm_description": "Treatment with Sacituzumab Govitecan",
            "arm_suspended": "N"
          },
          {
            "arm_code": "Arm B",
            "arm_internal_id": 2222,
            "arm_description": "Control",
            "arm_suspended": "N"
          }
        ],
        "step_code": "1",
        "step_type": "Registration",
        "step_internal_id": 1111,
        "match": [
          {
            "and": [
              {
                "clinical": {
                  "oncotree_primary_diagnosis": "Invasive Breast Carcinoma",
                  "her2_status": "Negative"
                }
              }
            ]
          }
        ]
      }
    ]
  }
}